<DOC>
	<DOCNO>NCT01567527</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled trial ass time recurrence mood episode subject bipolar I disorder maintain stability aripiprazole IM depot least 8 week . This trial include male female subject 18 65 year age , inclusive , diagnosis bipolar I disorder , accord DSM-IV-TR criterion confirm Mini International Neuropsychiatric Interview ( MINI ) , experience least one previous manic episode sufficient severity require hospitalization and/or treatment mood stabilizer antipsychotic agent addition current manic episode . All subject must experience manic episode ( per DSM-IV-TR criterion ) YMRS total score ≥ 20 trial entry . Both inpatient outpatient eligible trial . This trial consist screen phase follow 4 treatment phase . Subjects undergo screen eligibility , follow conversion oral aripiprazole monotherapy phase , need , oral aripiprazole stabilization phase , single-blind aripiprazole IM depot stabilization phase , , double-blind , placebo-controlled phase .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Intramuscular Formulation Aripiprazole ( OPC-14597 ) Maintenance Treatment Bipolar I Patients</brief_title>
	<detailed_description />
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Key 1 . Male female subject 18 65 year age , inclusive , time informed consent . 2 . Subjects current diagnosis bipolar I disorder , define DSMIVTR criterion confirm MINI history least one previous manic mixed episode manic symptom sufficient severity require one follow intervention : hospitalization and/or treatment mood stabilizer , and/or treatment antipsychotic agent , addition current manic episode . `` Require '' define intervention occur rather one recommend . Rapid cyclers 8 few episode previous year include . 3 . Subjects currently experience manic episode YMRS total score ≥20 Screening Visit . 4 . Subjects inpatient outpatient status prior entry Phase C ( IM depot stabilization ) . 5 . In investigator 's opinion , subject able understand nature trial follow protocol requirement , include prescribed dosage regimen , tablet ingestion , aripiprazole IM depot injection , discontinuation prohibit concomitant medication ; read understand write word order complete subjectreported outcome measure ; reliably rat assessment scale . Key 1 . Subjects current Axis I ( DSMIVTR ) diagnosis bipolar I disorder . 2 . Subjects NOT experience least one previous manic mixed episode manic symptom sufficient severity require one follow intervention : hospitalization and/or treatment mood stabilizer , /or treatment antipsychotic agent , exclude current manic episode . `` Require '' define intervention occur rather one recommend . 3 . Subjects bipolar I disorder consider resistant/refractory treatment manic symptom history . 4 . Subjects unresponsive clozapine treatment mania . 5 . Subjects significant risk commit suicide base history , mental status examination , investigator 's judgment , CSSRS answer `` yes '' question 4 5 ( current within last 90 day ) . 6 . Subjects current manic episode duration &gt; 2 year . 7 . Subjects currently ( within past month ) meet DSMIVTR criterion substance abuse substance dependence ; include abuse alcohol benzodiazepine , excludes use caffeine and/or nicotine . 8 . Subjects history evidence medical condition would expose undue risk significant adverse event ( AE ) interfere assessment safety efficacy course trial , include limited hepatic , renal , respiratory , cardiovascular , endocrine , neurologic , hematologic , immunologic disease determine clinical judgment investigator . 9 . Subjects currently experience mixed depressive episode ( per DSMIVTR criterion ) . 10 . Subjects history hypersensitivity antipsychotic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Aripiprazole</keyword>
	<keyword>Intramuscular ( IM ) Depot</keyword>
	<keyword>Bipolar</keyword>
</DOC>